Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Strong-Buy

Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by stock analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Saturday.

A number of other analysts have also recently commented on MIRM. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. JMP Securities set a $95.00 target price on Mirum Pharmaceuticals in a research note on Wednesday, November 5th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Finally, Citizens Jmp upped their price target on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research note on Friday, December 19th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $102.00.

Mirum Pharmaceuticals Stock Down 1.4%

NASDAQ:MIRM opened at $91.05 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The firm’s 50-day moving average price is $75.05 and its 200-day moving average price is $69.41. The company has a market capitalization of $4.68 billion, a PE ratio of -105.87 and a beta of 0.48. Mirum Pharmaceuticals has a 1-year low of $36.88 and a 1-year high of $93.70.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. Mirum Pharmaceuticals’s quarterly revenue was up 47.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.30) earnings per share. On average, equities analysts predict that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. MCF Advisors LLC boosted its holdings in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after acquiring an additional 185 shares during the last quarter. Quantbot Technologies LP bought a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $33,000. Comerica Bank boosted its holdings in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the last quarter. Quarry LP purchased a new stake in Mirum Pharmaceuticals in the third quarter worth approximately $41,000. Finally, CWM LLC grew its position in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after purchasing an additional 161 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.